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Abstract
The test-negative design (TND) has become a standard approach for vaccine effectiveness
(VE) studies. However, previous studies suggested that it may be more vulnerable than
other designs to misclassification of disease outcome caused by imperfect diagnostic tests.
This could be a particular limitation in VE studies where simple tests (e.g. rapid influenza
diagnostic tests) are used for logistical convenience. To address this issue, we derived a math-
ematical representation of the TND with imperfect tests, then developed a bias correction
framework for possible misclassification. TND studies usually include multiple covariates
other than vaccine history to adjust for potential confounders; our methods can also address
multivariate analyses and be easily coupled with existing estimation tools. We validated the
performance of these methods using simulations of common scenarios for vaccine efficacy
and were able to obtain unbiased estimates in a variety of parameter settings.
Introduction
Vaccine effectiveness (VE) is typically estimated as the vaccine-induced risk reduction of the
target disease (TD) and has been traditionally studied using cohort or case–control designs.
However, the test-negative design (TND) is becoming a popular alternative design for VE
studies [1, 2]. This is a modified version of the case–control study with an alternative defin-
ition of the control group; traditional case–control studies usually define controls as non-
disease individuals in the study population, while TND studies use individuals with similar
symptoms to the TD but presenting negative test results (i.e. patients of non-target diseases;
ND). The TND can therefore minimise ascertainment bias by including only medically-
attended patients in both case and control groups. Many TND studies have focused on
influenza vaccination, but recent studies have also considered other diseases including
pneumococcal disease [3, 4] and rotavirus disease [5–7].
Despite its increasing popularity, a TND can be more vulnerable than other study designs
to misclassification of disease outcome. Multiple studies have shown that VE is underestimated
when the diagnostic tests used in the study are imperfect (i.e. have a sensitivity and/or a spe-
cificity less than 100%) [8–10]. This can be a particular issue when simple tests (e.g. rapid
diagnostic tests) are used for logistical convenience, as simple tests tend to have lower diagnos-
tic performance than more advanced tests (e.g. polymerase chain reaction; PCR). Previous
studies evaluated the expected degree of bias and concluded that specificity had a more
important effect on bias than sensitivity [8–11]. These findings appear to support the use
of rapid tests, despite limited sensitivity, because the specificity of these tests is typically
high [2]. However, theoretical studies to date have been based on a limited range of assump-
tions about efficacy and pathogen epidemiology; it is therefore unclear whether such conclu-
sions hold for all plausible combinations of scenarios.
If a study is expected to generate a non-negligible bias in estimation, such bias needs to be
assessed and – if possible – corrected before the estimate is reported. Greenland [12] proposed
a bias correction method for cohort studies where the sensitivity and specificity of the test are
known (or at least assumed). However, it has been pointed out that bias correction in case–
control studies is in general difficult because of differential recruitment, whereby the probabil-
ity of recruiting (test-positive) cases and (negative) controls may be different [12, 13].
Although TND studies are often considered to be special cases of case–control studies, they
are free from the issue of differential recruitment because the recruitment and classification
are mutually-independent [14]. This means that, while Greenland’s method does not apply
to TND as-is, another type of bias correction may still be possible. For example, De Smedt
et al. have characterised the misclassification bias in VE in the TND in a simulation study
[10]. One limitation of their formulation was it relies on the unobserved âœtrueâ disease
risk being known, where in reality this is not usually measurable in field studies. As a result,
bias correction methods for TND studies that are directly applic-
able to field data have not yet been proposed. Moreover, previous
analysis of misclassification bias has not considered the impact of
multivariate analysis, where potential confounders (e.g. age and
sex) are also included in the model used to estimate VE.
To address these issues, we develop a bias correction method
for the test-negative VE studies that uses only data commonly
available in field studies. We also apply these methods to multi-
variate analyses. As our approach uses the so-called multiple over-
imputation (MO) framework (generalisation of multiple
imputation) [15], it can easily be coupled with a wide range of
estimation tools without modifying their inside algorithms.
Finally, we evaluate the performance of our methods by simula-
tions of plausible epidemiological scenarios.
Methods and results
Characterising bias in TND studies
First, we consider the case where only vaccination history is
included as a risk factor of acquiring the TD (i.e. the univariate
setting). Following the approach of Haber et al. [16], we consider
four steps in the case reporting process: vaccination, onset of
symptoms, seeking of medical care and diagnosis. For simplicity,
let us assume that occurrence of TD and ND are mutually inde-
pendent, where their prevalences in the unvaccinated population
are represented as r1 and r0, respectively
1. Let nV and nU be the
vaccinated and unvaccinated population size. The target variable
in VE studies is γ, the relative risk of TD in the vaccinated popu-
lation relative to the unvaccinated (i.e. VE = 1− γ). Vaccinated
and unvaccinated population can have different likelihoods of
seeking medical treatment given disease. We denote by mV and
mU the probability of medical attendance given ND in vaccinated
and unvaccinated population, respectively.
As our focus in the present study is the bias in VE estimation
caused by imperfect tests, we made two key assumptions follow-
ing Haber et al. [16]. One assumption is that vaccines have no
effect on the risk of ND. This enables ND patients to be eligible
for a control group and is a key assumption in TND studies.
The other assumption is that the probability of medical attend-
ance in vaccinated and unvaccinated population given infection
is constant regardless of the disease (TD or ND). The probability
of medical attendance given TD may be different from ND (mV
and mU), potentially due to difference in severity; we assume
that these probabilities are obtained by multiplying a constant fac-
tor μ (i.e. μmV and μmU)
2. These assumptions may not always
hold and TND can be biased in such cases. However, we assume
that they do in the following analysis to keep our focus on mis-
classification bias; namely, the study was assumed to be able to
provide an unbiased VE estimate if tests are perfect.
Following the above notations, we can classify the vaccinated
and unvaccinated population into multiple categories shown in
Table 1. We can characterise different VE study designs (cohort,
case–control and test-negative) by the categories in Table 1 from
which each design tries to sample: the cohort design samples from
populations nV and nU and follows them up to see what propor-
tions fall into xV and xV; the case–control design samples from
medically-attended cases (xV + xU) and non-diseased controls
(nV− xV + nU− xU) and calculate the odds ratio to approximate
the relative risk (however, the actual studies can mismeasure
these variables when misclassificaiton is present).
In TND studies, medically-attended patients (xV + xU + yV +
yU) are sampled and classified into four categories based on the
test result and vaccine history. Let q be the proportion sampled
relative to the population. Denoting the observed case counts
with misclassification by X and Y, the process of data collection











where α and β are the sensitivity and specificity of the test,
respectively. Matrix
C = a 1− b
1− a b
[ ]
describes the conversion from the true disease state to the
observed result. We hereafter refer to C as the classification
matrix. The determinant c = |C| = α + β − 1 is the Youden index
of the test and satisfies 0 < c≤ 1 (if c < 0, the test is not predictive
and the definitions of positive/negative should be swapped).
Youden index indicates the level of information retained in the
potentially misclassified test results. Youden index of 0 indicates
that the information is completely lost and the test is no better
than random guesses.
We define bias in the VE estimate to be the absolute difference
between the (raw) estimate, derived from the misclassified obser-
vation, and the true value. Let δ = ((r1μ)/r0) be the odds of the
(medically-attended) TD in the unvaccinated population. Then
the expected bias B is given as a function of four independent
parameters, α, β, γ and δ:
B(a, b, g, d) =VEraw − VEtrue
= (1− graw)− (1− gtrue)
= g− [agd+ (1− b)][(1− a)d+ b][(1− a)gd+ b][ad+ (1− b)] .
(2)
This suggests that the influence of sensitivity/specificity on the
degree of bias varies depending on the case ratio δ/(1 + δ), i.e.
the ratio between the incidence of medical attendance for TD
and ND in the unvaccinated study population3 (Fig. 1). The
degree of bias also depends on γ but is independent of mV and
mU. The degree of bias is largely determined by the test specificity
when the case ratio is small, but the influence of sensitivity and
specificity is almost equivalent to a case ratio of 0.6. It is notable
that high specificity does not always assure that the bias is negli-
gible. This may be true if specificity is strictly 100% and the case
ratio is low to moderate, but a slight decline to 97% can cause a
bias up to 10–15 percentage points. The effect of sensitivity is
also non-negligible when the case ratio is high.
When the expected bias is plotted against the case ratio with
various combinations of test performance, we find that VE esti-
mates can be substantially biased for certain case ratios (especially
1It has been suggested that a possible violation of this assumption occur as a result of
virus interference [17], but conclusive evidence for this is currently lacking [18, 19] and
the effect on VE estimates may be limited in any case [20].
2This may not be true, for example, if vaccination reduces the severity of TD and
hence reduces the likelihood of medical attendance.
3For example, a case ratio of 0.5 indicates TD:ND = 1:1 in the unvaccinated. The value
is smaller than 0.5 when TD <ND and greater than 0.5 when TD >ND.
2 A. Endo et al.
when the ratio is far from 1:1), even with reasonably high sensi-
tivity and specificity (Fig. 2b). In TND studies, researchers have
no control over the case ratio because the study design requires
that all tested individuals be included in the study. We found
that the proportion of TD-positive patients in previous TND
studies (retrieved from three systematic reviews [21–23]) varied
considerably, ranging from 10% to 70% (Fig. 2a)4. Because of
this large variation in the case ratio, it would be difficult to predict
the degree of bias before data collection. Post-hoc assessment and
Table 1. Population classified into different categories of interest in VE studies
Vaccinated Unvaccinated
Notation Mean Notation Mean
All nV nV nU nU
Infected by TD − γr1nV − r1nU
Medically-attended (true) TD patients xV μmVγr1nV xU μmUr1nU
Test-positive TD patients x+V αμmVγr1nV x+U αμmUr1nU
Test-negative TD patients x−V (1− α)μmVγr1nV x−U (1− α)μmUr1nU
Infected by ND − r0nV − r0nU
Medically-attended (true) ND patients yV mVr0nV yU mUr0nU
Test-positive ND patients y+V (1− β)mVr0nV y+U (1− β)mUr0nU
Test-negative ND patients y−V βmVr0nV y−U βmUr0nU
Fig. 1. Bias in VE estimates caused by misclassification for different combinations of parameter values. (a)–(c) Estimated VE plotted against sensitivity. (a) True case
ratio (the true ratio between TD and ND cases included in the study) = 0.2 (b) 0.4 (c) 0.6. Each two sets of lines respectively correspond to different true VEs (80%
and 40%, denoted by the dotted lines). (d)–(f) Estimated VE plotted against specificity. (d) True case ratio = 0.2 (e) 0.4 (f) 0.6.
4Strictly speaking, proportion positive is a different quantity from case ratio, but it
should serve as a reasonable proxy of the case ratio in most settings.
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correction therefore need to be considered. See the Supplementary
Document for further analysis of the degree of bias.
Bias correction in univariate analysis
Corrected odds ratio
Although TND has sometimes been referred to as a special case of
the case–control design, there is a distinct feature in the sampling
procedure of TND. It has been pointed out that the adjustment
methods for misclassification bias developed for cohort studies
do not apply to case–control studies because the sampling ratio
in case–control studies (differential recruitment) varies between
case and control groups [12, 13]. However, as we have shown
in Section ‘Characterising bias in TND studies’, both cases (TD
patients) and controls (ND patients) are sampled at the same
ratio (q) in TND studies. This suggests that the existing bias cor-
rection formulas developed for a hypothetical setting [13] where
the whole population is evenly sampled (which is unrealistic in
traditional studies) may be applicable to TND studies.
By left-multiplying Equation (1) with the inverted matrix C−1,
we can obtain the corrected odds ratio γ* as
g∗= XV − ((1− b)/b)YV
YV − ((1− a)/a)XV ·
YU − ((1− a)/a)XU
XU − ((1− b)/b)YU , (3)
which adjusts for misclassification to give an asymptotically-
unbiased estimate of γ. This result can also be derived by maxi-
mising the likelihood accounting for misclassification in the
observed TND data (see the Supplementary Document).
All four components of (3) (two numerators and two denomi-
nators) are usually expected to be non-negative with moderate VE
(less than 100%) because these components are considered to be
proportional to reconstructed true case counts. However, in some
(relatively rare) cases, one or more components may become
negative due to random fluctuations in observation.
Theoretically, negative values are not permitted as true case
counts, and thus such negative quantities would need to be trun-
cated to 0. As a result, the corrected odds ratio can be either 0 or
infinity. It is unrealistic in clinical settings that vaccines have
absolute 100% or −100% effectiveness. Uncertainty around such
MLEs should be carefully considered; increasing sample size or
redesigning the study might be recommended where possible.
Alternatively, the Bayesian framework may be used to yield an
interval estimate with the likelihood shown in section ‘Direct like-
lihood method for the logistic regression model’ adapted for a
univariate model.
The confidence interval for VE can be obtained by assuming
log-normality of the odds ratio γ, i.e.
g = g∗ exp (+1.96s∗),
where σ is the shape parameter of the log-normal distribution and
is empirically given as
s∗ = SD(log (g∗))
= c

XVYV (XV + YV )
[aYV − (1− a)XV ]2[bXV − (1− b)YV ]2
+
XUYU (XU + YU )
[aYU − (1− a)XU ]2[bXU − (1− b)YU ]2
√√√√√√√ .
(4)
See the Supplementary Document for details of the MLE and
confidence intervals.
Simulation
To assess the performance of the corrected odds ratio given in
Equation (3) and uncertainty around it, we used simulation stud-
ies. TND study datasets were drawn from Poisson distributions
(see the Supplementary Document for model settings and the
likelihood function) as it is a reasonable assumption when medically-
attended cases are recruited over the study period. We parame-
terised the mean incidence in the dataset by the ‘baseline medical
attendance’ λV = qmV(r1μ + r0)nV and λU = qmU(r1μ + r0)nU, so
that λV and λU correspond to the mean number of vaccinated/
unvaccinated patients when vaccine has no effect (i.e. γ = 1 and
VE = 0). The mean total sample size (given as ((1 + γδ)/(1 + δ))
λV + λU) was set to be 3000. Parameter values were chosen accord-
ing to a range of scenarios shown in Table 2, and the true VE=1
−γ was compared with the estimates obtained from the simulated
data. For each scenario, simulation was repeated 500 times to yield
the distribution of estimates. Reproducible codes (including those
Fig. 2. Biased VE estimates with varying case ratio and the observed proportion of positive patients. (a) The proportion of test-positive patients in TND studies from
systematic reviews. The proportions were retrieved from three systematic reviews [21–23]. (b) Estimated VE plotted against case ratio. Two sets of lines respectively
correspond to different true VEs (80% and 40%, denoted by the dotted lines). The histogram in Panel (a) is overlaid on the x-axis.
4 A. Endo et al.
for simulations in later sections) are reposited on GitHub (https://
github.com/akira-endo/TND-biascorrection/).
We found that the uncorrected estimates, directly obtained
from the raw case counts that were potentially misclassified,
exhibited substantial underestimation of VE for most parameter
values (Fig. 3). On the other hand, our bias correction method
was able to yield unbiased estimates in every setting, whose
median almost correspond to the true VE. Although the corrected
and uncorrected distributions were similar (with a difference in
median ∼5%) when VE is relatively low (40%) and the test has
sufficiently high sensitivity and specificity (95% and 97%, respect-
ively), they became distinguishable with a higher VE (80%). With
Table 2. Simulation settings
ID Scenario True VE (γ) λV/λU Case ratio (γ/(1 + γ)) Sensitivity (α) Specificity (β)
1 Baseline: low VE 0.4 0.5 0.5 0.8 0.95
2 Baseline: high VE 0.8 0.5 0.5 0.8 0.95
3 High quality test: low VE 0.4 0.5 0.5 0.95 0.97
4 High quality test: high VE 0.8 0.5 0.5 0.95 0.97
5 Low quality test: low VE 0.4 0.5 0.5 0.6 0.9
6 Low quality test: high VE 0.8 0.5 0.5 0.6 0.9
7 High TD incidence: low VE 0.4 0.5 0.7 0.8 0.95
8 High TD incidence: high VE 0.8 0.5 0.7 0.8 0.95
9 Low TD incidence: low VE 0.4 0.5 0.3 0.8 0.95
10 Low TD incidence: high VE 0.8 0.5 0.3 0.8 0.95
11 High vaccine coverage: low VE 0.4 0.7 0.5 0.8 0.95
12 High vaccine coverage: high VE 0.8 0.7 0.5 0.8 0.95
13 Low vaccine coverage: low VE 0.4 0.3 0.5 0.8 0.95
14 Low vaccine coverage: high VE 0.8 0.3 0.5 0.8 0.95
Fig. 3. Bias correction for simulated data in the univariate setting. The distributions of bias-corrected VE estimates (boxplots in blue) are compared with those of
raw VE estimates without correction (red). Five hundred independent datasets were randomly generated for each set of parameter values, and the corrected and
uncorrected VE estimates are compared with the true value (black solid line). See Table 2 for parameter settings in each scenario.
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lower test performances, the bias in the VE estimates can be up to
10–20%, which may be beyond the level of acceptance in VE
studies.
Bias correction of VEs reported in previous studies
We have seen that the degree of bias for uncorrected VE estimates
depends on parameter values. To explore the possible degree of
bias in existing VE studies, we extracted the reported crude VEs
(i.e. VEs unadjusted for potential confounders) from two system-
atic reviews [21, 23]5 and applied our bias correction method
assuming different levels of test sensitivity and specificity. The
case counts for each study summarised in the reviews were con-
sidered eligible for the analysis if the total sample size exceeded
200. Varying the assumed sensitivity and specificity, we investi-
gated the possible discrepancy between the reported VE (or
crude VE derived from the case counts if unreported in the
reviews) and bias-corrected VE. We did not consider correcting
adjusted VEs because it requires access to the original datasets.
Figure 4 displays the discrepancy between the reported VE and
bias-corrected VE corresponding to a range of assumptions on
the test performance. Many of the extracted studies employed
PCR for the diagnostic test, which is expected to have a high per-
formance. However, the true performance of PCR cannot be
definitively measured as there is currently no other gold-standard
test available. Figure 4 suggests that even a slight decline in the
test performance can introduce a non-negligible bias in some par-
ameter settings. Our bias correction methods may therefore also
be useful in TND studies using PCR, which would enable a sen-
sitivity analysis accounting for potential misdiagnosis by PCR
tests. In this light, it is useful that the corrected odds ratio
g∗=XV − ((1− b)/b)YV
YV − ((1− a)/a)XV ·
YU − ((1− a)/a)XU
XU − ((1− b)/b)YU
is a monotonic function of both α and β (given that all the four
components are positive). The possible range of VE in a sensitiv-
ity analysis is obtained by supplying γ* with the assumed upper/
lower limits of sensitivity and specificity.
Bias correction in multivariate analysis
Theoretical framework
TND studies often employ a multivariate regression framework to
address potential confounding variables such as age. The most
widespread approach is to use generalised linear models (e.g.
logistic regression) and include vaccination history as well as
other confounding variables as covariates. The estimated linear
coefficient for vaccination history can then be converted VE (in
the logistic regression model, the linear coefficient for vaccination
history corresponds to log (1−VE)). In this situation, the likeli-
hood function now reflects a regression model and thus the bias-
corrected estimate in the univariate analysis (Equation (3)) is no
longer applicable. We therefore need to develop a separate multi-
variate TND study framework to correct for bias in multivariate
analysis.
Suppose that covariates ξ = (ξ1, ξ2, …, ξn) are included in the
model, and that ξ1 corresponds to vaccination history (1: vacci-
nated, 0: unvaccinated). These covariates ξi, as well as outcome
variable Zi (i.e. test results) are available for each individual i
included in the study. In TND studies, it is often convenient to
model the binomial probability for the true outcome p1(ξi), i.e.
the conditional probability that the true outcome is TD as
opposed to ND given an individual has covariates ξi. Let us
use parameter set θ to model the binomial probabilities p1 (and
p0 = 1− p1). Using the binomial probability pZi for observed
(potentially misclassified) outcome Zi, we can obtain the MLE
for θ by maximising













1− a( )p1 ji; u
( )+ bp0 ji; u( )[ ].
(5)
With the estimate θ*, the VE estimate for an individual with
covariates ξ2:n = (ξ2, ξ3, …, ξn) is given as (1−odds ratio):
VE(j2:n) = 1− p1(j
1 = 1, j2:n; u∗)
p0(j
1 = 1, j2:n; u∗) /
p1(j
1 = 0, j2:n; u∗)
p0(j
1 = 0, j2:n; u∗) . (6)
See the Supplementary Document for further details.
Direct likelihood method for the logistic regression model
The logistic regression model is well-suited for modelling bino-










= u0 + u1j1 + · · · + unjn. (7)
Fig. 4. Bias correction method applied to published VE estimates assuming various
test sensitivity and specificity. Case count data were extracted from two systematic
reviews [21, 23]. Each connected set of dots show how (crude) VE estimates reported
in the review varies when imperfect sensitivity and specificity are assumed. Black
dots on the grey diagonal line denote the original VEs reported in the reviews.
This should correspond to the true value if sensitivity = specificity = 1. Coloured
dots show the bias-corrected VE considering potential misclassification.
5Young et al. [22] was not included because they did not report case counts.
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In the logistic regression model where covariate ξ1 indicates
vaccination history, the corresponding coefficient θ1 gives the
VE estimate: VE = 1− exp (θ1). Due to the assumed linearity,
the estimated VE value is common across individuals regardless
of covariates ξ2:n.
We can employ the direct likelihood method by combining
Equations (5) and (7). The usual logistic regression optimises θ
by assuming that the test results follow Bernoulli distributions
Zi∼ Bernoulli( p1(ξi;θ)) (Zi = 1 for positive test results and 0 for
negative). To correct the misclassification bias, we instead need
to use the modified probabilities to construct the likelihood
accounting for diagnostic error, i.e.
Zi  Bernoulli(p+(ji; u))
= Bernoulli(ap1(ji; u)+ (1− b)p0(ji; u)). (8)
Parameter θ is estimated by directly maximising the probability of
observing {Zi} based on Equation (8)
Note that as long as the binomial probability is the modelling
target, other type of models (e.g. machine learning classifiers)
could also be employed under a similar framework.
Multiple overimputation combined with existing tools
The direct likelihood method presented in the previous section is
the most rigorous MLE approach and would therefore be
preferable whenever possible. However, it is often technically-
demanding to implement such approaches as it involves
re-defining the likelihood; if we wanted to use existing tools for
logistic regression (or other models), for example, we would
need to modify the internal algorithm of such tools. This is in
particular complicated in tools for generalised linear models
including logistic regression, whose standard algorithm is the
iteratively reweighted least squares method [24], which does not
involve the explicit likelihood. To ensure that our correction
methods can be employed without losing access to substantial
existing software resources, we also propose another method,
which employs a MO framework [15] to account for misclassifi-
cation. Whereas multiple imputation only considers missing
values, MO is proposed as a more general concept which includes
overwriting mismeasured values in the dataset by imputation. In
our multivariate bias correction method, test results in the dataset
(which are potentially misclassified) are randomly overimputed.
Let M be an existing estimation software tool whose likelihood
specification cannot be reprogrammed. Given data d = {zi, ξi}i=1,2,…S,
where zi denotes the true disease state (z = 1 for TD and z = 0 for
ND), M would be expected to return at least the following two ele-
ments: the point estimate of VE (εd) and the predicted binomial
probability p̂1(ji) for each individual i. From the original observed
dataset D, J copies of imputed datasets {D̃
j
} = {D̃1, D̃2, . . . , D̃J } are
generated by the following procedure.
(1) For i = 1, 2, …, S, impute disease state z̃ji based on the test
result Zi. Each z̃
j
i is sampled from a Bernoulli distribution
conditional to Zi:
z̃ji 
Bernoulli(1− w̃i+) (Zi = 1)
Bernoulli(w̃i−) (Zi = 0)
{
. (9)
(2) w̃i+ and w̃i− are estimated probabilities that the test result for
individual i is incorrect (i.e. zi≠ Zi) given Zi. The sampling
procedure (9) is therefore interpreted as the test result Zi
being ‘flipped’ at a probability w̃i+ or w̃i−. Later we will dis-
cuss possible procedures to obtain these probabilities.
(3) Apply M to D̃
j = {z̃ji, ji} to yield a point estimate of VE (εj).
(4) Repeat (1) and (2) for j = 1, 2, …, J to yield MO estimates
{εj}j=1,…J.
Once MO estimates {εj} are obtained, the pooled estimate and
confidence intervals of VE are obtained by appropriate summary
statistics, e.g. Rubin’s rules [25]. As long as the estimated ‘flipping’
probabilities w̃i+ = (w̃i+, w̃i−) are well chosen, this MO proced-
ure should provide an unbiased estimate of VE with a sufficiently
large number of iterations J.
As a method to estimate the flipping probability w̃i+, here we
propose the parametric bootstrapping described as follows. Given
















Although the true binomial probabilities p0(ξi), p1(ξi) are
unknown, their estimators are derived with the inverted classifica-










w̃i+ = 1−P(zi = 1|Zi = 1)=
1−b





w̃i− = 1−P(zi = 0|Zi = 0)=
1−a






These probabilities can be computed provided the odds of the test
results π+ (ξi)/π−(ξi). We approximate this odds by applying esti-
mation tool M to the original data D; i.e. the predicted binomial
probability p̂1(ji) obtained from D is used as a proxy of π+ (ξi).
Generally it is not assured that true and observed probabilities
p1(ξi) and π+ (ξi) have the same mechanistic structure captured
by M; however, when our concern is limited to the use of model-
predicted probabilities to smooth the data D, we may expect forM
to provide a sufficiently good approximation. The above frame-
work can be regarded as a variant of parametric bootstrapping
methods as MO datasets are generated from data D assuming a
parametric model M. The whole bias correction procedure is pre-
sented in pseudocode (Fig. 5); sample R code is also available on
GitHub (https://github.com/akira-endo/TND-biascorrection/).
EM algorithm
Another possible approach to addressing misclassification is the
use of the EM algorithm, which has been proposed for case–
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control studies in a previous study (where differential recruitment
was not considered) [26]. Because of its methodological similarity,
the algorithm can also be applied to the TND. The original EM
algorithm presented in [26] would produce, if properly imple-
mented, the result equivalent to the direct likelihood approach.
However, the original EM algorithm requires that the model
can handle non-integer sample weights (which may not always
be assured). Moreover, computing confidence intervals in EM
algorithm can be complicated. We therefore recommend para-
metric bootstrapping as the first choice of bias correction method
when the direct likelihood approach is inconvenient.
Simulation of bias correction with parametric bootstrapping
To assess the performance of this method, we used the same
simulation framework as in the univariate analysis (Table 2). In
addition to vaccination history (denoted by ξ1), we consider
one categorical and one continuous covariate. Let us assume
that ξ2 represents the age group (categorical; 1: child, 0: adult)
and ξ3 the pre-infection antibody titre against TD (continuous).
Suppose that the population ratio between children and adults
is 1:2, and that ξ3 is scaled so that it is standard normally distrib-
uted in the population. For simplicity, we assumed that all the
covariates are mutually independent with regard to the distribu-
tion and effects (i.e. no association between covariates and no
interaction effects). The relative risk of children was set to be 2
and 1.5 for TD and ND, respectively, and a unit increase in the
antibody titre was assumed to halve the risk of TD (and not to
affect the risk of ND). The mean total sample size λ was set to
be 3000, and 500 sets of simulation data were generated for
each scenario. VE estimates were corrected by the parametric
bootstrapping approach (the number of iterations J = 100) and
were compared with the raw (uncorrected) VE estimates.
Figure 6 shows the distributions of estimates with and without
bias correction in the multivariate setting. Our bias correction
(parametric bootstrapping) provided unbiased estimates for all
the scenarios considered. Overall, biases in the uncorrected esti-
mates were larger than those in the univariate setting. In some
scenarios, the standard error of the bias-corrected estimates was
extremely wide. This was primarily because of the uncertainty
already introduced before misclassification rather than the failure
of bias correction (as can be seen in the Supplementary Fig. S3).
Larger sample size is required to yield accurate estimates in those
settings, as the information loss due to misclassification will be
added on top of the inherent uncertainty in the true data.
The number of confounding variables
We investigated how the bias in uncorrected VE estimates can be
affected by the number of confounding variables. In addition to
the vaccine history ξ1, we added a set of categorical/continuous
confounding variables to the model and assessed the degree of
bias caused by misclassification. The characteristics of the vari-
ables were inherited from those in section ‘Simulation of bias cor-
rection with parametric bootstrapping’: categorical variable ‘age’
and continuous variable ‘pre-infection antibody titre’. That is,
individuals were assigned multiple covariates (e.g. ‘categorical
variable A’, ‘categorical variable B’, …, ‘continuous variable A’,
‘continuous variable B’, …) whose distribution and effect were
identical to ‘age’ (for categorical variables) and ‘antibody titre’
(for continuous variables) in section ‘Simulation of bias correc-
tion with parametric bootstrapping’. No interaction between
Fig. 5. Multiple imputation with parametric bootstrapping.
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covariates was assumed. The covariate set in section ‘Simulation
of bias correction with parametric bootstrapping’ being baseline
(the number of covariates: (vaccine, categorical, continuous) =
(1, 1, 1)), we employed two more scenarios with a larger number
of covariates: (1, 3, 3) and (1, 5, 5).
The simulation results are presented in Figure 7. Overall, add-
itional confounding variables led to more severe bias in the uncor-
rected VE estimates towards underestimation. These results further
highlight the importance of bias correction when heterogeneous
disease risks are expected; VE estimates adjusted for many con-
founding variables can exhibit substantial misclassification bias.
Discussion
Misclassification caused by imperfect diagnostic tests can poten-
tially lead to substantial biases in TND studies. By considering
the processes involved in VE estimation, we have characterised
the degree of bias potentially caused by misclassification in dif-
ferent parameter settings, finding that VE can be noticeably
underestimated, particularly when the ratio between TD and
ND cases in the study data is unbalanced. To address this poten-
tial bias, we developed multiple bias correction methods that
provide unbiased VE estimates in both univariate and multivari-
ate settings. When the test sensitivity and specificity are known
or assumed, those values can be used to restore the true VE esti-
mate by a relatively simple statistical procedure. Using simula-
tions, we showed that our methods could successfully
eliminate the bias in VE estimates obtained from misclassified
data, although some uncertainty was introduced as a result of
the information loss.
We believe that our methods could therefore enable research-
ers to report unbiased VE estimates even when imperfect tests had
to be used. Such methods could also help in the scaling up of
TND studies, as tests with limited performance are usually inex-
pensive and logistically convenient.
Although TND is a relatively new study design, first appearing
in a publication in 2005 [27], it has gained broad popularity and is
becoming a standard approach in VE studies. One of the largest
factors that have contributed to its widespread use is the fact
that data collection can be completed within clinical setups [1].
Whereas cohort or case–control studies usually require additional
efforts including follow-up or recruitment of non-patients, TND
studies only involve patients visiting healthcare facilities with sus-
pects of certain diseases and thus routinely collected clinical data
can be easily adapted for analysis. VE studies of influenza, for
which TND is most frequently used, often use PCR as a diagnostic
tool for better data quality [23]. However, such studies usually
involve intensive effort and cost, and thus may only be feasible
by large-scale research bodies. Our bias correction methods
may open a possibility of wider use of clinical data especially in
settings where rapid tests are routinely used for diagnosis. For
example, rapid influenza diagnostic tests are routinely used for
outpatient clinics and hospitals in Japan, and such clinical data
have facilitated a number of TND studies [28–33]. Such studies
based on rapid tests could benefit from our methods, as it
would provide strong support for the validity of their estimates.
Our methods may also be useful in resource-limited settings or
for diseases without high-performance diagnostic tools.
Even in resourceful settings where high-performance tests are
available, the slight possibility of misclassification might not
Fig. 6. Bias correction for simulated data in the multivariate setting. The distributions of bias-corrected (blue) and uncorrected (red) VE estimates from 500 simula-
tions are compared. Dotted lines denote median and black solid lines denote the true VE. The parametric bootstrapping bias correction method was used for bias
correction.
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always be neglected. Although PCR tests are currently used as a
gold-standard for influenza diagnosis, their sensitivity and speci-
ficity may not be exact 100%; especially, the sensitivity of the test
depends not only on microbiological technique but also on the
quality of swab samples. In addition, it is suggested that the sen-
sitivity of PCR tests may change during the time course of infec-
tion [34] and be sufficiently high only during a limited time
window. Our simulation study also indicated that a high hetero-
geneity in individual characteristics in the study population
might increase the bias. Our methods could enable researchers
to implement sensitivity analysis by assuming the possible test
sensitivity and specificity in such cases.
Our bias correction methods are also intended to be reason-
ably straightforward for researchers to introduce. Existing estima-
tion tools including software libraries and packages are often used
in epidemiological analyses. Incorporating the MO approach, our
parametric bootstrapping bias correction method only involves
data manipulation and does not require modification of the esti-
mation algorithm. Once multiple sets of data are randomly gen-
erated, any type of analysis can be performed as long as the
results can be summarised over the MO datasets. Of particular
note is that our methods for multivariate analysis allow stratifica-
tion of sensitivity and specificity among individuals. Therefore,
the users can employ more complex misclassification mechanisms
including time-varying test performance or test performance
affected by individual characteristics. Datasets with a mixture of
different diagnostic tools [3, 35] can also be handled by applying
different values for each test.
There are some limitations to our study. We only focused on
misclassification of diagnosis (i.e. misclassified outcomes) and
did not consider misclassification of covariates (e.g. vaccine his-
tory and other confounding variables), which is another import-
ant type of misclassification in TND studies [10]. Further, it is
generally not easy to plausibly estimate the sensitivity and speci-
ficity for measurement of covariates (e.g. recall bias), which must
be known or assumed to implement bias correction. However, if
reliable estimates are available, an extension of our approach
may yield bias-corrected VE estimates in the presence of covariate
misclassification. Moreover, to keep our focus only on diagnostic
misclassification, our methods rested on the assumption that
other sources of bias in TND studies are non-existent or properly
addressed. Potential sources of bias in TND studies have been dis-
cussed elsewhere [16, 36, 37], and the researchers conducting
TND studies need to carefully consider the possibility of such
biases in addition to the diagnostic misclassification. Lastly, it
must be noted that our methods depend on the assumed test sen-
sitivity and specificity, and that misspecifying those values can
result in an improper correction. The sensitivity and specificity
of tests are usually reported by manufacturers in a comparison
of the test results with gold-standard tests; however, when such
gold-standard tests themselves are not fully reliable or when no
available test has satisfactory performance to be regarded as gold-
standard, specifying sensitivity and specificity of a test is in prin-
ciple impossible. Further, test performances reported by manufac-
turers might lack sufficient sample size or might not be identical
to those in the actual study settings. Use of composite reference
standards [38, 39] or external/internal validation approaches
[40] may help overcome these problems.
Although the presence of imperfect diagnosis limits the quality
of clinical data, such data can still hold useful information, and
Fig. 7. Bias in raw VE estimates from simulated data in the presence of different numbers of confounding variables. The distributions in red, purple and blue
correspond to uncorrected VE estimates in the presence of 2, 6 and 10 confounding variables in addition to the vaccination history.
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this information can be transformed into useful insights by
appropriate statistical processing. Our bias correction methods
were developed primarily for TND studies, but a similar approach
could be applied to broader classes of estimation problems with
misclassification. Potential areas for future analysis include exten-
sion to test data involving continuous quantitative measurements,
and coupling with dynamic transmission models. The value of
routinely collected data in healthcare settings has become widely
recognised with the advancement of data infrastructure, and we
believe our methods could help support the effective use of
such data.
Conclusion
Bias correction methods for the TND studies were developed to
address potential misclassification bias due to imperfect tests.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268820002058.
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Appendix
Mathematical notations in section ‘Methods and results’
Characterising bias in TND studies
r1, r0: prevalence of TD/ND in the unvaccinated
population
nV, nU: vaccinated and unvaccinated population size
γ: the relative risk of TD in the vaccinated popu-
lation relative to the unvaccinated (VE = 1− γ)
mV, mU: the probability of medical attendance given ND
in vaccinated/unvaccinated population
μ: factor for the probability of medical attendance
given TD in relative to that given ND
xV, xU, x+V, x+U, x−V, x−U,
yV, yU, y+V, y+U, y−V, y−U:
the expected number of cases in the population;
see Table 1 for definitions
XV, XU, YV, YU: the observed case counts subject to
misclassification
q: the proportion of study samples relative to the
total population
α, β: sensitivity and specificity of the test
C: the classification matrix
c: the Youden index of the test; the determinant of
C δ: odds of medically-attended TD in the
unvaccinated population
Bias correction in univariate analysis
γ*: corrected odds ratio
σ*: shape parameter of the log-normal distribution that gives the confi-
dence interval of γ* (see Equation (4))
λV, λU: ‘baseline medical attendance’, the mean number of vaccinated/
unvaccinated patients when vaccine has no effect (VE = 0)
Bias correction in multivariate analysis
ξ = (ξ1, ξ2, …, ξn): covariates included in the model, where xi1 denotes vac-
cination history
Zi, zi: observed test result and true disease state for individual i
p1(ξ), p0(ξ): probability that the true test result is positive/negative for
an individual with covariates ξ
θ, θ*: model parameter for p1(ξ) and its estimate
pZi (ji): probability for the observed test result Zi
z̃ji: imputed disease state of individual i in the j-th imputed
dataset D̃
j
f̃i+, f̃i−: estimated probability that the test result for individual i is
incorrect
εj: point estimate for VE from the j-th imputed dataset D̃
j
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